DGAP-News: Exiqon launches new products for the research and development of LNA(tm) based drugs
ID: 495898
10.10.2011 08:45
---------------------------------------------------------------------------
Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value products for
gene expression analysis, today announced the expansion of its product offering
to include LNA(tm) products for the research and development of RNA targeted
medicine including LNA(tm) as the active pharmaceutical ingredient.
The first new products being offered include the following:
-- oxy-LNA(tm) amidites in kilogram quantities
-- LNA(tm) oligonucleotides in gram quantities
-- miRCURY LNA(tm) microRNA Inhibitors in gram quantities
Exiqon can now also offer fully paid up, non-exclusive, manufacturing licenses
to customers who want to manufacture or have manufactured oxy-LNA(tm) amidites for
their research programs. Exiqon does not grant licenses to the manufacturing,
research, development or sale of LNA(tm) based drugs for clinical trials or
otherwise.
In a comment, Senior Vice President Sales&Marketing, Dr. Henrik M.
Pfundheller said: 'We are excited to expand our product offering following
clarification that Santaris Pharma a/s does not have exclusive rights to supply
products for the research and development of LNA(tm) based drugs. Next generation
sequencing technology has revealed the complexity of the transcriptome,
however, the biological functionality of the RNA molecules are by far not
understood. With these products, Exiqon can now supply customers wishing to
conduct high throughput target identification and target validation studies and
eventually validate such targets in vivo.'
More information is available at Exiqon's website: http://www.exiqon.com/
Additional information:
Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)
See the full press release in the attached PDF or at
www.exiqon.com/investor/portal.
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=364337
News Source: NASDAQ OMX
10.10.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Exiqon A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0060077758
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.10.2011 - 08:45 Uhr
Sprache: Deutsch
News-ID 495898
Anzahl Zeichen: 3352
Kontakt-Informationen:
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 303 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Exiqon launches new products for the research and development of LNA(tm) based drugs"
steht unter der journalistisch-redaktionellen Verantwortung von
Exiqon A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
